Member Info for Marmited

.

What a mess this has become. So many shenanigans going on with this share from top to bottom. The sooner those who want out are out, and those who want in are in the better. TB maybe a clever man and has certainly killed sentiment but as far as I am concerned the jury is currently out on that one because the tech remains incredible regardless. Whether Covid ends tomorrow or not is now irrelevant as this test is broad across many pathogens including Sepsis, just choose the Aptamer and good to go. HIV, choose the Aptamer and good to go, Hepatitis, choose the Aptamer and good to go. Shenanigans and more shenanigans.. frustrating!

To clarify, I can’t see the likes of GSK buying /manufacturing Covid or any other pathogen tests It’s not their bag.

I agree, I can’t see the likes of GSK buying or producing devices from Paraytec. They have however been advising the U.K. government and most likely other Gov’s worldwide regarding scaling up testing and innovation and we do have their ears since this Covid test was spun from the miniature device which we were working with them on and completed in 2020. Fuji is a different case, they could manufacture the test. Paraytec already have global licensing deals and manufacturing with Malvern Panalytical and Pion for Actipix. The Covid device is using some of the Actipix tech so it would be easy to get a deal signed, but to date it looks like TB has other plans? Not really sure how this is going to move forwards but it absolutely will, it’s just too good to ignore for so so so many reasons.
The shareprice will do what it’s going to do in the meantime and just the same as positives talk up the price, negatives talk down the price, actually.. the real truth is... No one knows and both camps are simply just noise.

Ummm....

In 2020 we completed a programme of work in a project entitled “Towards a condensed platform for aggregation profiling”. Other partners in the consortium were Malvern Panalytical, CPI, UCLan, AstraZeneca, Fujifilm Diosynth Biotechnologies and GSK, with funding support provided by Innovate UK. Paraytec’s detector technology was incorporated into a prototype miniaturized instrument designed to characterise critical quality attributes of therapeutic proteins and virus like particles (VLPs) that are used to deliver new gene therapy drugs. Results have been disseminated at national and international conferences, and a poster is available here.

All the below plus endless future pathogen unknowns can be identified by our device in under 2 mins.

Current valuation £23m.

Covid and variants test

It is also a sepsis test

https://pubmed.ncbi.nlm.nih.gov/28119514/

It is also a

A HIV test

A Hepatitis B test

A Hepatitis C test

A SARS test

A H5N1 avian influenza test

An Ebola test

https://pubmed.ncbi.nlm.nih.gov/25690797/

And others - WHO Emerging and Dangerous Pathogens

Marburg, Rift Valley fever, Plague, Monkeypox, Lassa Fever, Tularaemia, MERS-CoV, Nipah, Legionellosis, Borreliosis, Melioidosis

https://www.who.int/csr/bioriskreduction/laboratorynetwork/en/

A Cancer test

Consequently, the adaptation of aptamer-based technologies to actual cancer diagnosis methods could provide a great opportunity for advances in cancer detection.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160954/

All the above have been confirmed via RNS because..

“It may be used with various labelling chemistries such as aptamers or antibodies, depending on the user's needs and this enables adoption of this technology for the identification of other pathogens, or the new variants of COVID-19 that are beginning to emerge worldwide. “

‘The team will now take this data to commercial partners and potential licensees, who have requested this information.’

Our commercial partners are as per the information on Paraytec website.

Malvern Panalytical, CPI, UCLan, AstraZeneca, Fujifilm Diosynth Biotechnologies and GSK

Days later, the ICMR DG wrote back to the state Health Secretary that ICMR has taken inputs from virology laboratories across the country to arrive at a single Ct value cut-off. All patients with a Ct value less than 35 may be considered as positive while those with a Ct value above 35 may be considered as negative, ICMR said.

https://www.google.co.uk/amp/s/indianexpress.com/article/explained/explained-the-ct-value-in-a-covid-test-7291682/lite/

Paraytec’s device

Using a maximum cycle threshold (Ct) value of 37, Paraytec's q-PCR testing regime has a sensitivity and specificity of 97.4% and 100% respectively.

It isnt 2 minutes, it’s 10 minutes. Anyway, regardless, it could take 10 seconds, it would still need a PCR to confirm if your were positive which takes another 24-48hrs at best, and it will still miss pre infectious and post infectious states and therefore give false readings due to its limited range of sensitivity. It’s just another basic LFT to add to the ever increasing list available.
We are going way beyond that targeting standards of testing at PCR levels. LFT’s at 2 mins, 10 mins, 15 mins don’t come anywhere near as close offering to identify the infected v the non infected, just the infectious. Looks like we can knock of 1 to 2 days off of this process and with scale. Move over LFT’s and PCR, we are coming through.

We don’t need miracles, just science. It is not Professor Carl’s test. It is a combination of Paraytec’s award winning technology (Actipix) Professor Carl’s reader/knowledge and expertise and Aptamers Aptamer.

Aptamer-based diagnostic platform granted US Patent

The first use of aptamers to detect viruses and other pathogens.

The platform provides a basis for an accurate COVID-19 test.

The invention is based on the field of aptamers, short molecules complementary to the protein and other molecular sequences, that are well suited for finding and binding to target sequences with very high specificity and affinity.

“This diagnostic platform has the potential to change the way we test for viruses and other pathogens,” says Najeeb Khalid, the company’s CEO and one of the co-inventors. “By simply changing the aptamer, tests for HIV, Zika, Influenza, Lyme and Legionnaire’s disease, along with tests for future coronavirus and its mutations, will be realized.”

Paraytec’s device is very very very similar. And already in final clinical trial :-)

https://www.pharmiweb.com/press-release/2021-04-28/aptamer-based-diagnostic-platform-granted-us-patent

You won’t find many in the caring for people professions anything other than critical of the right. Let’s leave politics out of it.

Resolving the COVID-19 pandemic requires diagnostic testing to determine which individuals are infected and which are not.

The current gold standard is to perform RT-PCR on nasopharyngeal samples. Best-in-class assays demonstrate a limit of detection (LoD) of ~100 copies of viral RNA per milliliter of transport media.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302192/

Braveheart RNS

Paraytec's test requires only 0.1 millilitres of sample fluid to undertake a successful test. This is a substantially smaller volume than is required for the current gold standard qPCR test used to extract material from a nasopharyngeal swab and indicates that the Paraytec test may be capable of detecting as few as 100 virions in a sample.

Worth absorbing these figures above. Looking like Joe public being capable of achieving an automated gold standard PCR level lab test equivalent in under 120 seconds.

I believe this is the kind of quality we should expect when the tech we own attracts the likes of GlaxoSmithKline, Astra Zeneca and Fujifilm to work on projects for end users. Very exciting times!

I’ve been thinking alone those same lines.

As you can see below, Carl Smythe tweeted back at the beginning of September that they were planning on engaging with the government scheme, Operation Moonshot, which has set aside £100 billion, with the aim of expanding testing to 10 million a day by early 2021. It is therefore our belief that after the proof of concept success a couple of months ago, Paraytec have in fact engaged with the government, and we expect an update on this very soon, hopefully by January or February at the latest. This theory aligns with Braveheart returning most of their free cash to investors, as we believe this shows confidence that Paraytec will receive sufficient funding from the government to scale up and mass produce their test. We would not be surprised to see Paraytec partner up with, or even being bought out by a large pharmaceutical company such as GSK, AstraZeneca, etc., if the government decides that their test is good for widespread roll out.

https://charlie-price.medium.com/why-braveheart-investment-group-share-price-will-5x-in-the-new-year-41e0fa414a96

An old article but it is an interesting view knowing the web Paraytec have with Glaxo, Astra and more combined with Sheffield Uni.

And Professor Carl’s reputation, along with Sheffield Uni would be shot!

Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.

http://www.ucmsr.com/meminfo/36

Ugh, I should have typed social media speculation not press.
It’s late! Bedtime!

I don’t think they would be interested in our test as such that they would produce and supply it. However, they do have the attention and access to ears, globally. Paraytec’s Covid test is designed around numerous key features which are deliberate end user designs.
So here is a mind bending question..were Paraytec ‘asked’ to design a Covid test following the completion of the program? Newspaper article from April 2020... funny, now look at the timing ref RNS Paraytec/Press Speculation and Covid test plans in May.

https://www.bloomberg.com/news/articles/2020-04-03/gsk-astrazeneca-in-talks-to-help-u-k-government-on-virus-tests